GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zai Lab Ltd (NAS:ZLAB) » Definitions » Debt-to-EBITDA

ZLAB (Zai Lab) Debt-to-EBITDA : -0.27 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Zai Lab Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zai Lab's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $77.9 Mil. Zai Lab's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $5.8 Mil. Zai Lab's annualized EBITDA for the quarter that ended in Jun. 2024 was $-307.4 Mil. Zai Lab's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was -0.27.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Zai Lab's Debt-to-EBITDA or its related term are showing as below:

ZLAB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.26   Med: -0.05   Max: -0.02
Current: -0.26

During the past 9 years, the highest Debt-to-EBITDA Ratio of Zai Lab was -0.02. The lowest was -0.26. And the median was -0.05.

ZLAB's Debt-to-EBITDA is ranked worse than
100% of 269 companies
in the Biotechnology industry
Industry Median: 1.5 vs ZLAB: -0.26

Zai Lab Debt-to-EBITDA Historical Data

The historical data trend for Zai Lab's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zai Lab Debt-to-EBITDA Chart

Zai Lab Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -0.11 -0.07 -0.02 -0.05 -0.04

Zai Lab Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 -0.05 -0.03 -0.32 -0.27

Competitive Comparison of Zai Lab's Debt-to-EBITDA

For the Biotechnology subindustry, Zai Lab's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zai Lab's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zai Lab's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Zai Lab's Debt-to-EBITDA falls into.



Zai Lab Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Zai Lab's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(7.104 + 8.047) / -365.111
=-0.04

Zai Lab's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(77.879 + 5.803) / -307.376
=-0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.


Zai Lab  (NAS:ZLAB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Zai Lab Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Zai Lab's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Zai Lab Business Description

Traded in Other Exchanges
Address
4560 Jinke Road, Jinchuang Plaza, Building 1, 4th Floor, Pudong, Shanghai, CHN, 201210
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Executives
Richard Gaynor director C/O NEON THERAPEUTICS, 40 ERIE STREET, SUITE 110, CAMBRIDGE MA 02139
Edmondson Frazor Titus Iii officer: Chief Legal Officer 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Joshua L Smiley officer: Chief Operating Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Yajing Chen officer: Chief Financial Officer 314 MAIN STREET, 4TH FLOOR, SUITE 100, CAMBRIDGE MA 02142
Rafael Amado officer: See Remarks 210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Ying Du director, officer: Chairwoman & CEO C/O ZAID LAB LIMITED, 4560 JINKE ROAD, BLDG. 1, 4F, PUDONG, SHANGHAI F4 201210
Harald Reinhart officer: Chief Medical Officer 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Peter Wirth director 37 HANCOCK STREET, BOSTON MA 02114
John D Diekman director C/O 5 AM VENTURES, 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Tao Fu director, officer: President & COO 3175 HANOVER STREET, PALO ALTO CA 94304
Scott W Morrison director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT SUITE 101, SOUTH SAN FRANCISCO CA 94080
Cho William Ki Chul officer: Chief Financial Officer 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210
Kai-xian Chen director 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR, PUDONG, SHANGHAI F4 201210